Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Dec 15, 2025 · Filed Dec 16, 2025
Gilead Sciences's Chief Commercial Officer sold $366K of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$366,000
Shares × reported transaction price
46 days after results of Oct 30, 2025, 57 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $119.78 on Dec 15, 2025, 34% above its 52-week low and 6% below its high, little changed over the previous 30 trading days
52-week range $89.14 (Jan 8, 2025) to $128.07 (Nov 19, 2025), 79% of the way up, from 250 adjusted closes. 30 trading days earlier: $119.79 on Oct 31, 2025. Describes the past only, not a forecast
A WARN layoff notice covering 17 workers was filed in California on November 12, 2025.
From the official state WARN list, 33 days before the trade; 1 more notice by the company within 60 days. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.5% | +2.8% | +0.7% |
| 30 days | +2.9% | +3.0% | -0.1% |
| 90 days | +19.0% | -0.1% | +19.1% |
| 180 days | +2.4% | +12.4% | -10.0% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Derivative exercise or conversion — not an open-market buy.